Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 4 September 2018 to Question 167276 on haemophilia: medical treatments, if he will provide figures on total expenditure on factor treatments for (a) factor VIII and (b) factor IX products for each fiscal year from 2007-08 to 2017-18.

The following table provides an estimate of combined expenditure on Factor treatments for Factor VIII and Factor IX products for fiscal years from 2007/08.

Combined expenditure is anticipated to be in excess of the values quoted in the following table. Since 2007/08, a number of updated frameworks have been published including that for recombinant Factor VIII in April 2014 with considerably lower prices which has reduced expenditure.

A combined estimate of total expenditure on Factor VIII and Factor IX products has been provided due to commercial confidentiality.

It is not possible to provide a breakdown between product areas for commercial reasons as this is likely to disclose pricing.